Skip to main contentAI and Advanced
/
RPGLIFE · NSEBSE SENSEX74,314.59-0.03%BSE |
NIFTY 5023,270.6+0.23%NSE |
NIFTY BANK56,055.75-0.42%NSE |
NIFTY IT29,155.6+0.23%NSE |
NIFTY AUTO27,159.15+0.99%NSE |
NIFTY FMCG45,572.7+0.03%NSE |
NIFTY PHARMA26,579.25+1.66%NSE |
NIFTY 50022,654.65+0.54%NSE |
RP
NSE · Equity shares · Biotechnology & Drugs68.90 · 2.52%
RPG Life Sciences RPGLIFE
NSE:INR 2,808
BSE:INR 2,810
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
AI analysis and Advanced tools for RPGLIFE
Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 2,739.1
Day rangeINR 2,696.8 — INR 2,889
52-week rangeINR 1,731.25 — INR 3,082
Volume18,681
Market cap4,403.98
P/E31.69
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)707.52
Net Income (INR Cr)115.17
Rev Growth (5 Year %)12.7
EPS Growth (5 Year %)23.55
P/E Ratio31.69
EPS67.87
Research path: Interpret RPG Life Sciences's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
RPGLIFERPG Life Sciences1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 793.16 | 657.81 | 512.87 |
| Accumulated Depreciation Total | -60.24 | -46.36 | -54.34 |
| Cash Equivalents | 134.77 | 26 | 17 |
| Other Liabilities Total | 10.85 | 7.45 | 7.06 |
| Accrued Expenses | 14.1 | 13.29 | 29.18 |
| Long Term Debt | 13.33 | Not available | Not available |
| Common Stock Total | 13.23 | 13.23 | 13.23 |
| Other Current Assets Total | 1.84 | 1.52 | 1.21 |
| Prepaid Expenses | 4.98 | 2.45 | 3.05 |
| Total Assets | 793.16 | 657.81 | 512.87 |
| Current Portof LT Debt/Capital Leases | 6.67 | Not available | 0 |
| Additional Paid-In Capital | 34.44 | 34.46 | 34.46 |
| Cash | 15.69 | 2.7 | 2.72 |
| Total Equity | 605.35 | 530.53 | 374.85 |
| Long Term Investments | 1.01 | 1.01 | 1.01 |
| Retained Earnings(Accumulated Deficit) | 557.68 | 482.84 | 327.16 |
| Total Common Shares Outstanding | 1.65 | 1.65 | 1.65 |
| Property/Plant/Equipment Total-Gross | 271.96 | 211.5 | 236.15 |
| Tangible Book Valueper Share Common Eq | 361.11 | 307.01 | 209.7 |
| Total Liabilities | 187.81 | 127.28 | 138.02 |
| Total Debt | 20 | 0 | 0 |
| Short Term Investments | 123.91 | 235.9 | 106.15 |
| Cashand Short Term Investments | 274.37 | 264.6 | 125.87 |
| Total Receivables Net | 149.84 | 101.17 | 64.34 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 |
| Deferred Income Tax | 3.06 | Not available | Not available |
| Accounts Receivable-Trade Net | 117.61 | 87.78 | 49.26 |
| Property/Plant/Equipment Total-Net | 211.72 | 165.13 | 181.81 |
| Total Current Liabilities | 160.57 | 119.83 | 130.96 |
| Total Inventory | 128.45 | 95.51 | 103.62 |
| Accounts Payable | 97.25 | 79.39 | 71.02 |
| Other Currentliabilities Total | 42.55 | 27.15 | 30.76 |
| Total Long Term Debt | 13.33 | 0 | 0 |
| Intangibles Net | 8.11 | 22.76 | 28.03 |
| Other Long Term Assets Total | 7.43 | 1.43 | 1.01 |
| Note Receivable-Long Term | 5.41 | 2.23 | 2.92 |
| Total Current Assets | 559.48 | 465.25 | 298.09 |
| Capital Lease Obligations | Not available | Not available | 0 |
Fundamentals
Valuation and ratios
Valuation
PEG Ratio1.93
Price to Sale Ratio6.22
Growth
Debt 5Yr CAGR %58.17
Margins
Operating Margin 12m18.6
Operating Margin 5y Avg21.41
Net Profit Margin 12m16.29
Net Profit Margin 5y17.44
Yield
Dividend Yield %0.89
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskBalanced risk
Board Risk44.19
Analyst consensus
Analyst consensus unavailable.
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Sun Pharmaceutical Industries | INR 1,944 | 4.66 L | 38.4 | — |
| Divi's Laboratories | INR 8,291.55 | 2.20 L | 73.32 | — |
| Torrent Pharmaceuticals | INR 4,965 | 1.89 L | 72.73 | — |
| Cipla | INR 1,475 | 1.19 L | 27.57 | — |
| Zydus Lifesciences | INR 1,106.25 | 1.10 L | 21.19 | — |
Shareholding
Ownership
- Promoter
- 72.95%
- FII
- 0.95%
- MF
- 0.04%
- Other
- 26.06%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Strong Momentum Meets Stretched Valuations as RPG Life Sciences Ltd Reaches All-Time High - MarketsMojoMarket news · 20 Jul 2026, 10:51 am
Strong Momentum Meets Stretched Valuations as RPG Life Sciences Ltd Reaches All-Time High MarketsMojo
RPG Life Sciences Ltd is Rated Hold - MarketsMojoMarket news · 20 Jul 2026, 12:01 am
RPG Life Sciences Ltd is Rated Hold MarketsMojo
RPG Life Sciences Ltd Hits All-Time High of Rs 3,009.60 as Momentum Builds Across Timeframes - MarketsMojoMarket news · 16 Jul 2026, 9:45 am
RPG Life Sciences Ltd Hits All-Time High of Rs 3,009.60 as Momentum Builds Across Timeframes MarketsMojo
RPG Life Sciences Ltd Surges 7.3% to Day's High of Rs 2905.55 — Outperforms Sector by 5.34 Percentage Points - MarketsMojoMarket news · 15 Jul 2026, 1:37 pm
RPG Life Sciences Ltd Surges 7.3% to Day's High of Rs 2905.55 — Outperforms Sector by 5.34 Percentage Points MarketsMojo
RPG Life Sciences partners with Archerchem to launch India’s first Naproxen–Esomeprazole combination - Indian Pharma PostMarket news · 14 Jul 2026, 12:49 pm
RPG Life Sciences partners with Archerchem to launch India’s first Naproxen–Esomeprazole combination Indian Pharma Post
RPG Life Sciences partners with Archerchem Healthcare for Naprosyn ES launch - Express PharmaMarket news · 14 Jul 2026, 11:02 am
RPG Life Sciences partners with Archerchem Healthcare for Naprosyn ES launch Express Pharma
Corporate actions
Events
- board MeetingsQuarterly Results
- annual General MeetingAGM
- dividendRs.24.0000 per share(300%)Final Dividend
- board MeetingsAudited Results & Final Dividend
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- dividendRs.4.0000 per share(50%)Special Dividend
Rusaka Markets Community
Discussion and sentiment for RPG Life Sciences
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Checking your Rusaka Markets account…
Company profile
Business information
What the company does
RPG Life Sciences Limited is an India-based research-based pharmaceutical company. The Company operates in the domestic and international markets in the formulations, generics, and synthetic active pharmaceutical ingredients (APIs) space. Its business portfolio includes domestic formulations, international formulations, and APIs. Its domestic formulation business manufactures and markets branded finished dosage formulations in India. The domestic formulations business has a presence in nephrology, oncology, rheumatology, cardiology, respiratory, pain management, vitamins & minerals, gastroenterology, and gynecology & pediatrics. The International Formulations business operates in the generics and branded generics space across Canada, Europe, Australia, New Zealand, and South America. Its products include Azoran, Mofetyl, Arpimune ME, Azathioprine, Quinfamide, Nicorandil, Haloperidol, Risperidone, Tolvaptan, Spironolactone, Sertraline, Naprosyn, Teristrong, and others.
Company facts
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- NSE Code
- RPGLIFE
- BSE Code
- 532983
Questions
Stock FAQ
What is the symbol and ISIN of RPG Life Sciences?
RPG Life Sciences has the symbol RPGLIFE and ISIN - INE105J01010.
What is the current price of RPG Life Sciences?
RPG Life Sciences is currently trading at INR 2,808.00.
What are the year high and year low of RPG Life Sciences?
RPG Life Sciences has a year high of INR 3,082.00 and a year low of INR 1,731.25.
What is the market capitalization of RPG Life Sciences?
RPG Life Sciences has a market capitalization of INR 4,403.98 crore.
What is the P/E ratio of RPG Life Sciences?
RPG Life Sciences has a P/E ratio of 31.69.
What is the dividend yield of RPG Life Sciences?
RPG Life Sciences has a dividend yield of 0.89%.
How is the financial performance of RPG Life Sciences based on revenue, net income, and EPS?
RPG Life Sciences has revenue of INR 707.52 crore, net income of INR 115.17 crore, and EPS of INR 70.65.
What is the book value of RPG Life Sciences?
RPG Life Sciences has a book value of NA.
What is the debt-to-equity ratio of RPG Life Sciences?
RPG Life Sciences has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of RPG Life Sciences?
RPG Life Sciences has a price-to-book ratio of NA and a price-to-sales ratio of 6.22.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.